A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Neratinib (Primary) ; Capecitabine; Lapatinib
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms NALA
- Sponsors Puma Biotechnology
- 02 Aug 2017 Planned End Date changed from 1 May 2018 to 1 Feb 2019.
- 02 Aug 2017 Planned primary completion date changed from 1 May 2017 to 1 Feb 2019.
- 06 Jul 2017 According to a Puma Biotechnology media release, primary analysis of PFS will be available during the first half of 2018.